JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
- In the absence of kidney disease, production of altered APOL1 protein in the kidney is low.
- Inflammatory cytokines, by activating the Janus kinase-STAT (JAK-STAT) pathway trigger high production of altered APOL1 protein in kidney cells.
- High production of altered APOL1 protein in the kidney causes chronic kidney disease--which manifests as spillage of protein in the urine and reduced filtration.
- The goal of JUSTICE clinical trial is to determine whether inhibition of APOL1 protein production by baricitinib would slow down progression of APOL1-mediated kidney disease and reduce spillage of protein in the urine.
You may be eligible to participate in JUSTICE clinical trial If you meet the following criteria:
- Self-identified African American/Black
- Adults 18-70 years
- APOL1 genotype of G1G1, G1G2, or G2G2
- FSGS diagnosed by kidney biopsy or clinically diagnosed HTN-CKD
- Urine albumin ≥300 mg/g
- Estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2
- Able to provide written informed consent
WHAT TO EXPECT IF YOU PARTICIPATE IN JUSTICE TRIAL:
- Participants will be randomized to receive baricitinib or placebo control.
- Urine and a small blood sample will be collected monthly to monitor kidney function. Participants will be followed for 6 months.
- Participants will receive gift cards each month.
Study Drug is provided by Eli Lilly.
JOIN US TO DISCOVER A CURE FOR APOL1-MEDIATED KIDNEY DISEASE
Contact us to see if you are eligible to participate in JUSTICE ClinicalTrial